摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-hydroxy-6-(methylthio)-3-quinolinecarboxylic acid | 26893-18-5

中文名称
——
中文别名
——
英文名称
4-hydroxy-6-(methylthio)-3-quinolinecarboxylic acid
英文别名
4-hydroxy-6-(methylthio)quinoline-3-carboxylic acid;6-methylsulfanyl-4-oxo-1H-quinoline-3-carboxylic acid
4-hydroxy-6-(methylthio)-3-quinolinecarboxylic acid化学式
CAS
26893-18-5
化学式
C11H9NO3S
mdl
——
分子量
235.263
InChiKey
BKDBRYWQDVAUPK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    91.7
  • 氢给体数:
    2
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase
    摘要:
    RIP2 kinase is a central component of the innate immune system and enables downstream signaling following activation of the pattern recognition receptors NOD1 and NOD2, leading to the production of inflammatory cytokines. Recently, several inhibitors of RIP2 kinase have been disclosed that have contributed to the fundamental understanding of the role of RIP2 in this pathway. However, because they lack either broad kinase selectivity or strong affinity for RIP2, these tools have only limited utility to assess the role of RIP2 in complex environments. We present, herein, the discovery and pharmacological characterization of GSK583, a next-generation RIP2 inhibitor possessing exquisite selectivity and potency. Having demonstrated the pharmacological precision of this tool compound, we report its use in elucidating the role of RIP2 kinase in a variety of in vitro, in vivo, and ex vivo experiments, further clarifying our understanding of the role of RIP2 in NOD1 and NOD2 mediated disease pathogenesis.
    DOI:
    10.1021/acs.jmedchem.6b00211
  • 作为产物:
    描述:
    4-氨基茴香硫醚 、 sodium hydroxide 作用下, 以 二苯醚乙醇 为溶剂, 反应 79.0h, 生成 4-hydroxy-6-(methylthio)-3-quinolinecarboxylic acid
    参考文献:
    名称:
    AMINO-QUINOLINES AS KINASE INHIBITORS
    摘要:
    公开号:
    EP2566477B1
点击查看最新优质反应信息

文献信息

  • Compounds and Methods of Treatment
    申请人:LACKEY Karen Elizabeth
    公开号:US20080234267A1
    公开(公告)日:2008-09-25
    A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.
    本文描述了一种作为Ret酪氨酸激酶抑制剂有用的衍生物。所述发明还包括使用相同物质治疗由不当的Ret酪氨酸激酶活性介导的疾病的方法。
  • GYRASE INHIBITORS
    申请人:Creighton Christopher J.
    公开号:US20130079323A1
    公开(公告)日:2013-03-28
    Novel gyrase inhibitors and related compositions and methods are useful for impeding bacterial growth. Compounds of Formula (I), are disclosed: Formula (I), wherein Y is N or CH; Z is N or CR 5 ; R 5 is H, a substituted or unsubstituted hydrocarbyl residue (1-3C) containing 0-2 heteroatoms selected from O, S and N, or is an inorganic residue; L is O, S, NR 7 , or CR 8 R 9 ; R 7 is H or C 1-3 alkyl; R 8 and R 9 are each independently H or C 1-3 alkyl; R 2 is H, a hydrocarbyl residue (1-40C) containing 0-10 heteroatoms selected from O, S and N optionally substituted with an inorganic residue; R 4 is H, an inorganic residue, or a hydrocarbyl residue (1-30C) containing 0-12 heteroatoms selected from O, S and N and containing 0-10 inorganic residues, wherein R 5 and R 4 together may join to form a fused ring; and R 6 is selected from the group consisting of H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, halo C 1-5 alkyl, halo C 2-5 alkenyl, halo C 2-5 alkynyl, C 1-5 hydroxyalkyl, C 1-5 alkyl chloride, C 2-5 alkenyl chloride, and C 2-5 alkynyl chloride; or a pharmaceutically-acceptable salt, ester, or prodrug thereof.
    新型螺旋酶抑制剂及相关组合物和方法,适用于阻碍细菌生长。其中公开了式(I)的化合物:式(I),其中Y为N或CH;Z为N或CR5;R5为H,含有0-2个来自O、S和N的杂原子的取代或未取代的基残基(1-3C),或为无机残基;L为O、S、NR7或CR8R9;R7为H或C1-3烷基;R8和R9各自独立地为H或C1-3烷基;R2为H,含有0-10个来自O、S和N的杂原子的基残基(1-40C),可选地取代为无机残基;R4为H、无机残基或含有0-12个来自O、S和N的杂原子和含有0-10个无机残基的基残基(1-30C),其中R5和R4可以共同形成融合环;R6选自H、C1-5烷基、C2-5基、C2-5炔基、卤代C1-5烷基、卤代C2-5基、卤代C2-5炔基、C1-5羟基烷基、C1-5氯代烷基、C2-5基和C2-5代炔基的群;或其药学上可接受的盐、或前药。
  • COMPOUNDS AND METHODS OF TREATMENT
    申请人:ANGELL RICHARD MARTYN
    公开号:US20110053934A1
    公开(公告)日:2011-03-03
    A derivative, which is useful as a ret kinase inhibitor is described herein. The described invention also includes methods of using the same in the treatment of diseases mediated by inappropriate ret kinase activity.
  • US9481675B2
    申请人:——
    公开号:US9481675B2
    公开(公告)日:2016-11-01
  • [EN] AMINO-QUINOLINES AS KINASE INHIBITORS<br/>[FR] AMINO-QUINOLÉINES EN TANT QU'INHIBITEURS DE KINASE
    申请人:GLAXO GROUP LTD
    公开号:WO2011140442A1
    公开(公告)日:2011-11-10
    Disclosed are quinoline compounds having the formula: wherein R1, R2 and A are as defined herein, and methods of making and using the same.
查看更多